Pulmonary arterial hypertension: An update

Netherlands Heart Journal

Volumn 19, Issue 12, 2011, Pages 514-522

  Hoendermis, E S ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Pulmonary arterial hypertension. diagnostics. therapy. review

Indexed keywords

AMBRISENTAN; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BOSENTAN; ENDOTHELIN RECEPTOR ANTAGONIST; ILOPROST; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; SILDENAFIL; SITAXSENTAN; TADALAFIL; TREPOSTINIL; UNCLASSIFIED DRUG;

ARTICLE; CARDIOPULMONARY EXERCISE TEST; CLINICAL FEATURE; COLOR; CONTINUOUS INFUSION; DIAGNOSTIC TEST; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DRUG RESPONSE; ECHOCARDIOGRAPHY; FOLLOW UP; HEADACHE; HEART CATHETERIZATION; HEART FAILURE; HOT FLUSH; HUMAN; HYPERTRANSAMINASEMIA; HYPOTENSION; INJECTION SITE PAIN; MYALGIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PERIPHERAL EDEMA; PHOTOSENSITIVITY; PROGNOSIS; PULMONARY HYPERTENSION; RISK FACTOR; SIDE EFFECT; TREATMENT OUTCOME;

EID: 83155187336     PISSN: 15685888     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12471-011-0222-1     Document Type: Article

References (50)

1. Galiè N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur heart J. 2009;30:2493-2537.
2. Humbert M, Morrell NW, Archer SL, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol. 2004;43:S13-S24.
3. Peacock AJ, Murphy NF, McMurray JJV, et al. An epidemiological study of pulmonary arterial hypertension. Eur Respir J. 2007;30:104-109.
4. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med. 2006;173:1023-1030.
5. Machado R, Eickelberg O, Elliott CG, et al. Genetics and genomics of pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54:S32-S42.
6. Sztrymf, Coulet F, Girerd B, et al. Clinical outcomes of pulmonary arterial hypertension in carriers of BMPR mutation. Am J Respir Crit Care Med. 2008;177:1377-1383.
7. Cabane J, Frances C, Launay D, et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: A French nationwide prospective multicenter study. Arthritis Rheum. 2005;52:3792-3800.
8. Hachulla E, Gressin V, Guillevin L, et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis. 2003;62:1088-1093.
9. Opravil M, Sereni D. Natural history of HIV-associated pulmonary arterial hypertension:trends in the HAART era. Aids. 2008; suppl 3: S35-S40.
10. Sitbon O, Lascoux-Combe C, Delfraissy JF, et al. Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era. Am J Respir Crit Care Med. 2008;177:108-113.
11. Le Pavec J, Souza R, Herve P, et al. Portopulmonary hypertension: survival and prognostic factors. Am J Respir Crit Care Med. 2008;178(6):637-643.
12. Duffels MGJ, Engelfriet PM, Berger RMF, et al. Pulmonary arterial hypertension in congenital heart disease: an epidemiologic perspective from a Dutch registry. Int J Cardiol. 2007;120(2):198-204.
13. Galie N, Manes A, Palazzini M, et al. Management of pulmonary arterial hypertension associated with congenital systemic-topulmonary shunts and Eisenmenger's syndrome. Drugs. 2008;68:1049-1066.
14. Lapa M, Dias B, Jardim C, et al. Cardiopulmonary manifestations of hepatosplenic schistosomiasis. Circulation. 2009;119(11):1518-1523.
15. van Loon RL, Roofthooft MT, Osch-Gevers M, et al. Clinical characterization of pediatric pulmonary hypertension: complex presentation and diagnosis. J Pediatr. 2009;155:176-182.
16. Humbert M, Maître S, Capron F, et al. Pulmonary edema complicating continuous intravenous prostacyclin in pulmonary capillary hemangiomatosis. Am J Respir Crit Care Med. 1998;157:1681-1615.
17. Mukerjee D, St George D, Knight C, et al. Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis. Rheumatology. 2004;43:461-466.
18. Arcasoy SM, Christie JD, Ferrari VA, et al. Echocardiographic assessment of pulmonary hypertension in patients with advance lung disease. Am J Respir Crit Care Med. 2003;167:735-740.
19. Hachulla E, Gressin V, Guillevin L, et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: A French nationwide prospective multicenter study. Arthritis Rheum. 2005;52:3792-3800.
20. Clayton LM, Jobsis MM, Crow JW, et al. Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension. J Am Coll Cardiol. 2002;39:1214-1219.
21. Forfia PR, Fisher MR, Mathai SC, et al. Tricuspid annular displacement predicts survival in pulmonary hypertension. Am J Respir Crit Care Med. 2006;174:1034-1041.
22. Hummel M, Hetzer R, Ewert R. Assessment of survival inpatients with primary pulmonary hypertension: importance of cardiopulmonary exercise testing. Circulation. 2002;106: 319-324.
23. Shah SJ, Thenappan T, Rich S, et al. Value of exercise treadmill testing in the risk stratification of patients with pulmonary hypertension. Circ Heart Fail. 2009;2:278-286.
24. Okajima Y, Ohno Y, Washko GR, et al. Assessment of pulmonary hypertension: What CT and MRI can provide. Acad Radiol. 2011;18:437-453.
25. Benza R, Biederman R, Murali S, et al. Role of cardiac magnetic resonance imaging in the management of patients with pulmonary arterial hypertension. J Am Coll Cardiol. 2008;52(21):1683-1692.
26. Hoeper MM, Lee SH, Voswinckel R, et al. Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. J Am Coll Cardiol. 2006;48:2546-2552.
27. Sitbon O, Humbert M, Jais X, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation. 2005;111:3105-3111.
28. Fijalkowska A, Kurzyna M, Torbicki A, et al. Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. Chest. 2006;129:1313-1321.
29. Johnson SR, Mehta S, Granton JT. Anticoagulation in pulmonary arterial hypertension: a qualitative systematic review. Eur Respir J. 2006;28(5):999-1004.
30. Galiè N, Begh M, Gat M, et al. Bosentan randomized trial of endothelin antagonist therapy-5 (BREATHE-5) Investigator. Bosentan therapy in patients with Eisenmenger Syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation. 2006;114:48-54.
31. Barbaro G, Luccini A, Pellicelli AM, et al. Highly active antiretroviral therapy compared with HAART and bosentan in combination in patients with HIV-associated pulmonary hypertension. Heart. 2006;92(8):1164-1166.
32. Cartin-Ceba R, Swanson K, Iyer V, et al. Safety and efficacy of ambrisentan for the treatment of portopulmonary hypertension. Chest. 2011;139(1):109-114.
33. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med. 1996;334:296-302.
34. Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension. A double-blind, randomized, placebo-controlled trial. AmJ Respir Crit CareMed. 2002;165:800-804.
35. Olschewski H, Simonneau G, Galie N, For the AIR Study Group, et al. Inhaled iloprost in severe pulmonary hypertension. N Engl J Med. 2002;347:322-329.
36. Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet. 2001;358(9288):1119-1123.
37. Humbert M, Barst RJ, Robbins IM, et al. BREATHE-2 combination of bosentan with epoprostenol in pulmonary arterial hypertension. Eur Respir J. 2004;24(3):353-359.
38. Sitbon O, McLaughlin VV, Badesch DB, et al. Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol. Thorax. 2005;60:1025-1030.
39. Galiè N, Rubin L, Hoeper M, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY Study). Lancet. 2008;371:2093-2100.
40. Galie N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the treatment of pulmonary arterial hypertension. Results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation. 2008;117:3010-3019.
41. Galie N, Ghofrani HA, Torbicki A, et al. The Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafil citrate therapy for pulmonary arterial hypertension. New Engl J Med. 2005;353:2148-2157.
42. Galie N, Brundage B, Ghofrani A, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation. 2009;119:2894-2903.
43. Hoeper MM, Markevych I, Spiekerkoetter E, et al. Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. Eur Respir J. 2005;26(5):858-863.
44. McLaughlin VV, McGoon MD. Pulmonary arterial hypertension. Circulation. 2006;114:1417-1431.
45. Quark R, Nawrot T, Meyns B, et al. C-reactive protein: a new predictor of adverse outcome in pulmonary arterial hypertension. J Am Coll Cardiol. 2009;53:1211-1218.
46. Henkens IR, van Wolveren SA, Gan CT, et al. Relation of resting heart rate to prognosis in patients with idiopathic pulmonary arterial hypertension. Am J Cardiol. 2009;103:1451-1456.
47. Simonneau G, Rubin L, Galie N, For the Pulmonary Arterial Hypertension combination Study of Epoprostenol and Sildenafil (PACES) Study Group, et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension. Ann Intern Med. 2008;149:521-30.
48. McLaughlin VV, Oudiz RJ, Frost A, et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit CareMed. 2006;174:1257-1263. combi.
49. Kurzyna M, Dabrowski M, Bielecki D, et al. Atrial eptostomy in treatment of end-stage right heart failure in patients with pulmonary hypertension. Chest. 2007;131:977-983.
50. Chen H, Shiboski SC, Golden JA, et al. Impact of the lung allocation score on lung transplantation for pulmonary arterial hypertension. Am J Respir Crit Care Med. 2009;180:385-387.